<DOC>
	<DOCNO>NCT01230710</DOCNO>
	<brief_summary>This open-label , single-arm study evaluate safety efficacy Tarceva ( erlotinib ) patient locally advanced metastatic non-small cell lung cancer complete 4 cycle standard platinum-based chemotherapy without progression . Patients receive Tarceva dose 150 mg orally daily disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Patients With Locally Advanced Metastatic Non-small Cell Lung Cancer Following 4 Cycles Platinum-based Chemotherapy Without Disease Progression</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient â‰¥ 18 year age . Histologically document nonsmall cell lung cancer ( NSCLC ) . Locally advanced recurrent ( Stage IIIB ) metastatic ( Stage IV ) disease . Completion 4 cycle acceptable , standard , platinumbased chemotherapy doublet without progression . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Patients reproductive potential must agree use effective contraception . Prior exposure agent direct human epidermal growth factor receptor ( HER ) axis ( eg , gefitinib , cetuximab , trastuzumab ) . Prior treatment monoclonal antibody therapy . Any malignancy within previous 5 year , except adequately treat carcinoma situ cervix squamous cell skin cancer . Clinically significant cardiovascular , hepatic , renal , metabolic disease active infection Preexisting interstitial lung disease . Human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>